Dark Pharma · DP-035
THE CURE COST EIGHTY-FOUR THOUSAND DOLLARS. THE LIVER PROGRAM IN TENNESSEE COULD TREAT NINE PATIENTS. WE MODELED FORTY-THREE THOUSAND.
Helicon Therapeutics set the price for Veridian at eighty-four thousand dollars per treatment, promising a ninety-four percent cure rate for hepatitis C. However, due to budget cuts, state Medicaid programs could only afford to treat nine out of two hundred seventeen eligible patients.
Case Assets
The Case Debrief is free to view. Full Case Study, Teaching Notes, Slide Deck, Discussion Guide, and Assessment are available with a Premium subscription.
Brief the Board
PREMIUM
🔒 Unlock
Learn the Case
FREE — included
Study the Case
PREMIUM
🔒 Unlock
Teach the Case
PREMIUM
🔒 Unlock
Present the Case
PREMIUM
🔒 Unlock
Run a Team Discussion
PREMIUM
🔒 Unlock
Test Your Judgement
PREMIUM
🔒 Unlock
Watch the Full Episode
The complete cinematic audio documentary — Dark Pharma
Unlock the Full Case Library
Get every Case Study, Slide Deck, Teaching Notes, Discussion Guide, and Assessment — across a growing library of business cases.
View Pricing →Related Cases
Cases that share a governance or behavioural model with this one.